Therese A Dolecek1, Emily Van Meter Dressler2, Jigisha P Thakkar3,4, Meng Liu2, Abeer Al-Qaisi3,4, John L Villano3,4. 1. Division of Epidemiology and Biostatistics and Institute for Health Research and Policy, School of Public Health, University of Illinois at Chicago, Chicago, Illinois. 2. Division of Cancer Biostatistics, University of Kentucky, Lexington, Kentucky. 3. Department of Medicine, University of Kentucky, Lexington, Kentucky. 4. Department of Neurology, University of Kentucky, Lexington, Kentucky.
Abstract
BACKGROUND: The current analysis follows the implementation of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, which mandated the collection of nonmalignant brain tumors. METHODS: Meningiomas were selected from the Surveillance, Epidemiology, and End Results (SEER) Program database for the years 2004 to 2011. Demographic and clinical characteristics, initial treatment patterns, and survival outcomes were evaluated using surveillance epidemiology statistical methods. RESULTS: The average annual age-adjusted incidence rate per 100,000 population was 7.62 (95 % confidence interval [CI], 7.55-7.68) for all meningiomas, 7.18 (95% CI, 7.12-7.25) for benign meningiomas, 0.32 (95% CI, 0.31-0.33) for borderline malignant meningiomas, and 0.12 (95% CI, 0.11-0.12) for malignant meningiomas. The annual rates increased for benign and borderline malignant tumors but decreased for malignant tumors. The rates for women exceeded those for men, especially for those with benign meningiomas. Black race was associated with significantly higher rates as was advancing age. Greater than 80% of tumors were located in cerebral meninges. Diagnostic confirmation through pathology occurred for approximately 50% of benign tumors, 90% of borderline malignant tumors, and 80% of malignant tumors. No initial treatment was reported for greater than 60% of benign tumors, 29% of borderline malignant tumors, or 31% of malignant tumors. The 5-year relative survival estimates for benign tumors, borderline malignant tumors, and malignant tumors were 85.6% (95% confidence interval [CI], 85%-86.2%), 82.3% (95% CI, 79.3%-84.8%), and 66% (95% CI, 60.6%-70.9%), respectively. Predictors of poorer survival were advanced age, being male gender, black race, no initial treatment, and malignant tumor behavior. CONCLUSIONS: The current analysis demonstrates that there is an increasing incidence of nonmalignant meningiomas, probably because of reporting learning curves associated with the implementation of Public Law 107-260. The high proportion of cases who receive no initial treatment is a survival outcome concern, especially for patients with malignant meningiomas.
BACKGROUND: The current analysis follows the implementation of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, which mandated the collection of nonmalignant brain tumors. METHODS:Meningiomas were selected from the Surveillance, Epidemiology, and End Results (SEER) Program database for the years 2004 to 2011. Demographic and clinical characteristics, initial treatment patterns, and survival outcomes were evaluated using surveillance epidemiology statistical methods. RESULTS: The average annual age-adjusted incidence rate per 100,000 population was 7.62 (95 % confidence interval [CI], 7.55-7.68) for all meningiomas, 7.18 (95% CI, 7.12-7.25) for benign meningiomas, 0.32 (95% CI, 0.31-0.33) for borderline malignant meningiomas, and 0.12 (95% CI, 0.11-0.12) for malignant meningiomas. The annual rates increased for benign and borderline malignant tumors but decreased for malignant tumors. The rates for women exceeded those for men, especially for those with benign meningiomas. Black race was associated with significantly higher rates as was advancing age. Greater than 80% of tumors were located in cerebral meninges. Diagnostic confirmation through pathology occurred for approximately 50% of benign tumors, 90% of borderline malignant tumors, and 80% of malignant tumors. No initial treatment was reported for greater than 60% of benign tumors, 29% of borderline malignant tumors, or 31% of malignant tumors. The 5-year relative survival estimates for benign tumors, borderline malignant tumors, and malignant tumors were 85.6% (95% confidence interval [CI], 85%-86.2%), 82.3% (95% CI, 79.3%-84.8%), and 66% (95% CI, 60.6%-70.9%), respectively. Predictors of poorer survival were advanced age, being male gender, black race, no initial treatment, and malignant tumor behavior. CONCLUSIONS: The current analysis demonstrates that there is an increasing incidence of nonmalignant meningiomas, probably because of reporting learning curves associated with the implementation of Public Law 107-260. The high proportion of cases who receive no initial treatment is a survival outcome concern, especially for patients with malignant meningiomas.
Authors: Jane H Cerhan; Alissa M Butts; Jeremy A Syrjanen; Jeremiah A Aakre; Paul D Brown; Ronald C Petersen; Clifford R Jack; Rosebud O Roberts Journal: Mayo Clin Proc Date: 2019-02 Impact factor: 7.616
Authors: Ammoren Dohm; Emory R McTyre; Michael D Chan; Claire Fan; Scott Isom; J Daniel Bourland; Ryan T Mott; Christina K Cramer; Stephen B Tatter; Adrian W Laxton Journal: J Clin Neurosci Date: 2017-09-13 Impact factor: 1.961
Authors: Gabrielle Truitt; Haley Gittleman; Rebecca Leece; Quinn T Ostrom; Carol Kruchko; Terri S Armstrong; Mark R Gilbert; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2019-06-17 Impact factor: 4.130
Authors: Suresh K Balasubramanian; Mayur Sharma; Danilo Silva; Vidhya Karivedu; Philipp Schmitt; Glen H Stevens; Gene H Barnett; Richard A Prayson; Paul Elson; John H Suh; Erin S Murphy; Samuel T Chao Journal: J Neurooncol Date: 2016-11-18 Impact factor: 4.130